SCHEMBL6289938

SCHEMBL6289938

CCOC(=O)c1cnc2snc(C)c2c1NC

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.42
KMT2A Q03164 3/20 0.40
PKM P14618 2/20 0.40
MEN1 O00255 2/20 0.40
NPSR1 Q6W5P4 2/20 0.39
RAB9A P51151 1/20 0.39
KDM4E B2RXH2 5/20 0.39
HSD17B10 Q99714 4/20 0.39
ALDH1A1 P00352 4/20 0.39
MAPT P10636 4/20 0.39
HPGD P15428 3/20 0.39
NPC1 O15118 2/20 0.39
MAPK1 P28482 2/20 0.39
RECQL P46063 1/20 0.39
PDE4B Q07343 2/20 0.38
HSP90AA1 P07900 1/20 0.38
PDE5A O76074 1/20 0.38
TSHR P16473 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6289418 0.82 KMT2A (0.55) POLBKMT2APKMMEN1NPSR1
SCHEMBL6289985 0.74 PKM (0.46) POLBKMT2APKMMEN1NPSR1
SCHEMBL6293949 0.74 KDM4E (0.46) POLBKMT2APKMMEN1KDM4E
SCHEMBL6293927 0.73 ALDH1A1 (0.58) POLBKMT2APKMKDM4EHSD17B10
SCHEMBL15413264 0.71 KDM4E (0.45) POLBKMT2APKMMEN1KDM4E
SCHEMBL24866746 0.69 KDM4E (0.43) POLBKMT2APKMMEN1KDM4E
SCHEMBL31164464 0.69 KDM4E (0.43) POLBKMT2APKMMEN1KDM4E
SCHEMBL4766455 0.69 HSP90AA1 (0.46) KMT2APKMMEN1RAB9AKDM4E
SCHEMBL6290750 0.69 NR3C1 (0.60) POLBKMT2AMEN1KDM4EHSD17B10
SCHEMBL18998177 0.68 MEN1 (0.73) KMT2APKMMEN1NPSR1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6946473-B2 Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors WYETH HOLDINGS CORPORATION (US) 2005-09-20 US disclosed
US-20030208066-A1 Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors AMERICAN CYANAMID COMPANY 2003-11-06 US disclosed
EP-1279674-A2 Acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors American Cyanamid Company (US) 2003-01-29 EP disclosed
EP-1157024-B1 ACETYLENIC ORTHO-SULFONAMIDO AND PHOSPHINIC ACID AMIDO BICYCLIC HETEROARYL HYDROXAMIC ACIDS AS TACE INHIBITORS AMERICAN CYANAMID CO (US) 2002-11-06 EP disclosed
EP-1157024-A1 ACETYLENIC ORTHO-SULFONAMIDO AND PHOSPHINIC ACID AMIDO BICYCLIC HETEROARYL HYDROXAMIC ACIDS AS TACE INHIBITORS American Cyanamid Company (US) 2001-11-28 EP disclosed
WO-2000044749-A1 ACETYLENIC ORTHO-SULFONAMIDO AND PHOSPHINIC ACID AMIDO BICYCLIC HETEROARYL HYDROXAMIC ACIDS AS TACE INHIBITORS AMERICAN CYANAMID COMPANY (US) 2000-08-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030208066-A1 Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors SI, TNF, PTDSS1 POLB 971/4885KMT2A 3583/4885PKM 3507/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.